Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Control Group, Mexico-based NSS FOPL, Brazil-based NSS FOPL
Interventions: Experimental : Mexico-based NSS FOPL, Experimental : Brazil-based NSS FOPL; Other
Lead sponsor: George Washington University; Other
Eligibility: 20 Years and older
Enrollment: 1,068 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Central Sleep Apnea Comorbid With Opioid Use
Interventions: Acetazolamide, Placebo; Drug
Lead sponsor: Sanjay R Patel; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: TBI (Traumatic Brain Injury)
Interventions: depth electrodes; Device
Lead sponsor: University of Minnesota; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
Interventions: Acolbifene Hydrochloride, Biospecimen Collection, Mammography, Questionnaire Administration, Random Periareolar Fine-Needle Aspiration, Tamoxifen; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 35 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Duarte, California • Chicago, Illinois • Kansas City, Kansas + 1 more

Conditions: Epiphora
Interventions: Atropine sulfate ophthalmic solution 0.005%, Vehicle arm; Drug
Lead sponsor: Rehan Ahmed; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: Houston, Texas • Mesquite, Texas

Conditions: Biliary Tract Cancers
Interventions: mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)], Durvalumab, Tremelimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Spinal Cord Injury
Interventions: TESS, Training, Motor Task, sham-TESS; Device · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Hines, Illinois

Conditions: Stepped Care Cognitive Behavioral Therapy, Exercise, Physical Activity, Anxiety Depression
Interventions: Stepped Care Mental Health Counseling, Exercise Program; Behavioral
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Tumor
Interventions: Nirogacestat; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hearing Loss, Dizziness, Vertigo, Fall Related Injury Risk, Fall Prevention, Imbalance, Speech Intelligibility
Interventions: Hearing aids equipped with motion sensing abilities; Device
Lead sponsor: Stanford University; Other
Eligibility: 55 Years and older
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Traumatic Brain Injury
Interventions: TRAIN-Vets, Health Education Control; Behavioral
Lead sponsor: Northern California Institute of Research and Education; Other
Eligibility: 50 Years to 89 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Palo Alto, California • San Francisco, California

Conditions: Multiple Myeloma
Interventions: BMS-986393, Alnuctamab, Mezigdomide, Iberdomide, Elranatamab, Dexamethasone; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 11 more

Conditions: Cyclic Neutropenia, Congenital Neutropenia, Neutropenia
Interventions: Serial Blood Count Study, Athelas Home device; Device
Lead sponsor: University of Washington; Other
Eligibility: 5 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 2 Diabetes
Interventions: Routine Care + Glycemic Excursion Minimization (RC+GEM), Routine Care (RC); Behavioral · Other
Lead sponsor: Chiara Fabris, PhD; Other
Eligibility: 30 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Charlottesville, Virginia

Conditions: Neuropathy, Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Interventions: Non-therapeutic Nerve Conduction Studies, Non-therapeutic assessment of patient-reported neuropathy; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Prostate Carcinoma
Interventions: Flotufolastat F-18 Gallium, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy; Drug · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Ductal Carcinoma in Situ, Breast Cancer
Interventions: Novel cavity marking technique; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Oral Cavity Squamous Cell Carcinoma
Interventions: NisinZ® P, Surgery (non-interventional, standard of care); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Mesial Temporal Lobe Epilepsy
Interventions: AAV9-hSyn1-miGRIK2; Genetic
Lead sponsor: UniQure Biopharma B.V.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 15 more

Conditions: Healthy Volunteers
Interventions: Xanomeline/ Trospium Chloride; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Anaheim, California • Lenexa, Kansas • San Antonio, Texas

Conditions: Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm, Nerve Sheath Neoplasm, Pituitary Gland Adenoma, Schwannoma
Interventions: Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration; Radiation · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Breast Cancer
Interventions: Epidiferphane, Taxane Chemotherapy; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Cancer Survivorship
Interventions: Supervised Exercise and Diet Program, Unsupervised Exercise and Diet Program; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Miami, Florida • Boston, Massachusetts

Conditions: HR-HPV Testing
Interventions: HR-HPV Testing; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 7,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

NSS Grocery Store Brazil

Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder

Depth Electrode Detection of Cortical Spreading Depolarization After Traumatic Brain Injury

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Low-Dose Atropine Eye Drops for Excessive Tearing (Epiphora)

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Spinal Cord Stimulation for Functional Recovery in Humans With Tetraplegia

Latinas Integrating Fitness and Therapy

Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study

Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device

TBI Rehabilitation and Activation in Veterans

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Serial Blood Count Study

Treating Early Type 2 Diabetes by Reducing Postprandial Glucose Excursions: A Paradigm Shift in Lifestyle Modification

A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique

Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisions

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study

Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients

Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study

Expanding Access to Cervical Cancer Screening Through Primary HR-HPV Testing and Self-sampling: a Multicomponent Intervention for Safety Net Health Systems